צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: 89bio Pharma (ETNB)

The high margin potential of 89bio, Inc. (ETNB) is based on the unique drug Pegozafermin and a patented FGF21 modification method. Year-over-year product sales dynamics for the TTM clearly illustrate this growth, where the value of 0.00 captures the metric level. Business development relies on partnerships with medical centers in liver therapy and complete independence from geopolitical risks within the protected humanitarian sector.
פילוחים אנליטיים של חברת 89bio, Inc.

For the biotechnology sector company 89bio, Inc. (ETNB), the commercialization of pegozafermin in the MASH market serves as the key value driver. This metric measures the relative change in rolling annual revenue compared to the same interval in the previous period, revealing the actual pace of business scaling. The 12-month annual revenue change trajectory on GURU.Markets visualizes this vector, separating random fluctuations from sustainable growth. Positive momentum will confirm the future potential for free cash flow.